Back to top
more

Elevance Health, Inc. (ELV)

(Real Time Quote from BATS)

$417.78 USD

417.78
1,204,241

-0.08 (-0.02%)

Updated Nov 5, 2024 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Universal Health (UHS) Q1 Earnings Beat on Higher Admissions

by Zacks Equity Research

Universal Health's (UHS) Q1 results reflect strong performance in acute care and behavioral health segments. Meanwhile, the elevated expense level partially offsets the positives.

Humana (HUM) Q1 Earnings Beat on Growing Membership & Premiums

by Zacks Equity Research

Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.

Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised

by Zacks Equity Research

Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.

Elevance Health (ELV) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Elevance Health (ELV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

HCA Healthcare (HCA) Beats on Q1 Earnings, Ups '23 EPS View

by Zacks Equity Research

HCA Healthcare's (HCA) first-quarter results gain from increased patient admissions. Management expects EPS within the $17.25-$18.55 band this year, higher than the previous view of $16.40-$17.60.

Elevance Health (ELV) Beats on Q1 Earnings, Hikes Profit View

by Zacks Equity Research

Elevance Health's (ELV) first-quarter results reflect growing premiums stemming from rate increases.

Elevance Health (ELV) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 2.16% and 2.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ELV or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. DOCS: Which Stock Is the Better Value Option?

Elevance Health (ELV) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Elevance Health's (ELV) first-quarter results are likely to reflect higher premiums, commercial and government sales figures and total expenses.

Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

If You Invested $1000 in Elevance Health a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Establishment Labs Holdings Inc. (ESTA) Stock Jumps 6.1%: Will It Continue to Soar?

by Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Zacks Analyst Blog Highlights SAP, Elevance Health, Diageo, SLB and Charter Communications

by Zacks Equity Research

SAP, Elevance Health, Diageo, SLB and Charter Communications are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for SAP, Elevance Health & Diageo

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Elevance Health, Inc. (ELV) and Diageo plc (DEO).

Here's Why Elevance Health (ELV) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Investors Should Retain Cigna (CI) Stock Now

by Zacks Equity Research

Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.

Elevance (ELV) to Divest Life & Disability Business to StanCorp

by Zacks Equity Research

With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.

ELV or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. DOCS: Which Stock Is the Better Value Option?

Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia

by Zacks Equity Research

The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

by Zacks Equity Research

Sector ETF report for IHF

Here's Why You Should Retain Elevance (ELV) in Your Portfolio

by Zacks Equity Research

Strong local presence, improving top line, membership hike and significant new contracts in its government business poise Elevance Health (ELV) well for growth.

The Zacks Analyst Blog Highlights UnitedHealth, Elevance Health, Humana and Centene

by Zacks Equity Research

UnitedHealth, Elevance Health, Humana and Centene are included in this Analyst Blog.

Kaibalya Pravo Dey headshot

Will Biden's Tax Hike Plan Extend Medicare's Life to 2050?

by Kaibalya Pravo Dey

U.S. President Joe Biden's proposal is also likely to enhance Medicare's ability to negotiate prices for drugs.

Select Medical (SEM) Q4 Earnings Miss Estimates, Revenues Up

by Zacks Equity Research

Select Medical (SEM) anticipates 2023 revenues to be within $6.5-$6.7 billion.